Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTC 
Benitec Biopharma Ltd ADR (BNTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: BNTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.86
1 Year Target Price $24.86
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.91% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 415.54M USD | Price to earnings Ratio - | 1Y Target Price 24.86 |
Price to earnings Ratio - | 1Y Target Price 24.86 | ||
Volume (30-day avg) 7 | Beta 0.41 | 52 Weeks Range 9.10 - 17.15 | Updated Date 10/23/2025 |
52 Weeks Range 9.10 - 17.15 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-09-23 | When - | Estimate -0.3129 | Actual -0.42 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.39% | Return on Equity (TTM) -52.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 263261434 | Price to Sales(TTM) 2770.13 |
Enterprise Value 263261434 | Price to Sales(TTM) 2770.13 | ||
Enterprise Value to Revenue 10457.68 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 26250469 | Shares Floating 12886355 |
Shares Outstanding 26250469 | Shares Floating 12886355 | ||
Percent Insiders 3.53 | Percent Institutions 91.09 |
Upturn AI SWOT
Benitec Biopharma Ltd ADR
Company Overview
History and Background
Benitec Biopharma Ltd ADR (BNTC) is a biotechnology company focused on the development of novel genetic medicines. Founded in 1997, it initially focused on RNA interference (RNAi) based therapeutics. Over time, it has evolved and expanded its pipeline to include DNA-directed RNA gene therapy.
Core Business Areas
- DNA-Directed RNA Gene Therapy: This segment focuses on developing therapies based on its proprietary DNA-directed RNA (ddRNA) platform technology.
- Clinical Development: This segment focuses on the clinical trials and development of its therapeutic candidates.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceuticals. Its organizational structure consists of research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- BB-301: BB-301 is a gene therapy being developed for Oculopharyngeal Muscular Dystrophy (OPMD). It's currently in clinical trials. Market share data specific to BB-301 is not publicly available as it is still in development. Competitors include companies developing alternative OPMD therapies, though gene therapy approaches are relatively novel in this space.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense research and development, high risk, and high reward. The gene therapy subsector is experiencing significant growth due to advances in gene editing and delivery technologies.
Positioning
Benitec Biopharma Ltd ADR is positioned as a specialized biotechnology company focusing on ddRNA-based gene therapies. Its competitive advantage lies in its proprietary technology and its focus on specific genetic diseases.
Total Addressable Market (TAM)
The TAM for gene therapies is estimated to be in the tens of billions of dollars. Benitec Biopharma's TAM depends on the success of its clinical trials and the market penetration of its products. It is well positioned within a specific niche, however its future performance depends on the success of its clincial trials
Upturn SWOT Analysis
Strengths
- Proprietary ddRNA technology platform
- Focus on underserved genetic diseases
- Experienced management team
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new therapeutic targets
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Financing risk and dilution
Competitors and Market Share
Key Competitors
- SRPT
- VRTX
- BLUE
Competitive Landscape
Benitec Biopharma Ltd ADR faces competition from larger pharmaceutical companies with more resources. Its competitive advantage lies in its proprietary technology and focus on specific genetic diseases. Market share percentages are estimated and based on gene therapy or related drug market segments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited and dependent on funding rounds and clinical trial advancements.
Future Projections: Future growth is highly dependent on the success of BB-301 and other pipeline candidates.
Recent Initiatives: Recent initiatives include advancing BB-301 through clinical trials and seeking strategic partnerships.
Summary
Benitec Biopharma Ltd ADR is a high-risk, high-reward biotechnology company. Its strengths lie in its proprietary technology and focus on underserved genetic diseases, but it faces significant challenges related to financing, clinical trial outcomes, and competition. Positive clinical trial results are crucial for the company's future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in biotechnology companies is highly speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Benitec Biopharma Ltd ADR
Exchange NASDAQ | Headquaters Hayward, CA, United States | ||
IPO Launch date 2015-08-18 | Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://benitec.com |
Full time employees 19 | Website https://benitec.com | ||
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.